Isomorphic Labs Raises $2.1 Billion Series B to Scale AI Drug Design Engine

Alphabet's Isomorphic Labs raised $2.1 billion in Series B funding led by Thrive Capital, with participation from Alphabet, MGX, Temasek, CapitalG, GV, and the UK Sovereign AI Fund. The London-based company, founded in 2021 as a DeepMind spinout and led by 2024 Nobel laureate Demis Hassabis, will use the capital to scale its IsoDDE AI drug design engine and advance therapeutic programs toward clinical trials expected by end of 2026. The company has signed drug discovery partnerships worth up to $3 billion with Eli Lilly and Novartis. Total outside capital now stands at approximately $2.6 billion.